scorecardresearch Skip to main content

AbbVie buying Cambridge biotech Cerevel for $8.7 billion

The deal comes less than a week after the Illinois-based pharmaceutical giant said it would acquire ImmunoGen of Waltham for more than $10 billion.

EyePoint data suggest time-released drug may help patients with macular degeneration
EyePoint’s stock price vaulted more than 180 percent to $18.56 a share, a gain of $11.90 on the Nasdaq exchange in mid-day trading.

INNOVATOR Q&A
Many Americans ration insulin to save money. One nonprofit is trying to make the life-saving drug more affordable.
Eric Moyal is the founder and executive director of Project Insulin, a Providence-based nonprofit working to ensure that every American has access to affordable insulin.

FDA poised to approve first gene-editing therapy, made by local drug firms
The life-changing drug, developed by Boston-based Vertex and its Swiss partner CRISPR Therapeutics, targets sickle cell disease, an inherited blood disorder that causes crippling pain.

AbbVie strikes deal to acquire Waltham’s ImmunoGen for more than $10 billion
It’s the largest acquisition of a Massachusetts company this year.

Generation Bio cuts its payroll by 40 percent in latest restructuring move
The Cambridge biotech startup is seeking to extend its cash into 2027.

More Life Sciences Headlines

AbbVie strikes deal to acquire Waltham’s ImmunoGen for more than $10 billion

It’s the largest acquisition of a Massachusetts company this year.

Generation Bio cuts its payroll by 40 percent in latest restructuring move

The Cambridge biotech startup is seeking to extend its cash into 2027.

Evelo Biosciences, a microbiome company launched by Flagship, shuts down

The Cambridge biotech is ceasing operations after running low on cash and seeing multiple drug trial failures.

Merck buys small Cambridge biotech for up to $610 million

Caraway Therapeutics is developing medicines to treat conditions such as Parkinson’s disease, ALS, and rare kidney diseases.

Flagship Pioneering launches new biotech with Mass., UK offices

Quotient Therapeutics, which will have offices in Mass. and the United Kingdom, wants to develop drugs that target illnesses caused by genetic changes that occur as people age.

Vertex sickle cell drug, based on novel gene-editing technology, wins approval in UK

The go-ahead comes about two weeks before the FDA is set to determine whether CRISPR and Boston-based Vertex can market the same drug in the United States, a much larger market.

The ‘bump factor’ returns to Kendall Square

Random meetings in the compact hub help to fuel the local biotech cluster — at least on Tuesdays through Thursdays.

Theseus lays off almost three-fourths of its staff

The Cambridge biotech is the latest biopharma firm in Massachusetts to slash its workforce in a prolonged industrywide shakeout that followed years of exuberant investment and growth.